Oxford's Parkinson's Gene Therapy Improves Symptoms

LONDON – Oxford BioMedica plc can now boast three years' safety data and a sustained improvement in symptoms in all 15 patients treated in the Phase I/II trial of its ProSavin gene therapy for Parkinson's disease, but needs to progress to a higher dose "to provide more certainty" that this is not just a placebo effect, and to be competitive against deep brain stimulation treatment.